VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
Education Center - SponsoredBringing specialist level interpretation in-clinicby • Zoetis DiagnosticsImagine a busy weekday morning in a typical small animal clinic. The appointments are fully booked, the phones are ringing, and in comes Yogi, a five year old terrier mix whose owners are clearly worried.
